Pierre Yves Scarabin
- Hormone replacement therapy and circulating ICAM-1 in postmenopausal women--a randomised controlled trialP Y Scarabin
INSERM, Cardiovascular Epidemiology Unit U258, Hopital Broussais, Paris, France
Thromb Haemost 81:673-5. 1999....
- Haemostasis in relation to dietary fat as estimated by erythrocyte fatty acid composition: the prime studyP Y Scarabin
INSERM Unité 258, Universite Paris Sud, Villejuif, France
Thromb Res 102:285-93. 2001..01). No relationships were found between fatty acids and fibrinogen, vWf, PAI-1 or factor VII. The results of this study suggest that consumption of n-3 fatty acids derived from fish may favourably influence tPA-ag...
- Plasma fibrinogen explains much of the difference in risk of coronary heart disease between France and Northern Ireland. The PRIME studyPierre Yves Scarabin
Cardiovascular Epidemiology Unit U258, INSERM, 16, avenue Paul Vaillant Couturier, 94807 Villejuif Cedex, France
Atherosclerosis 166:103-9. 2003..These findings add to the epidemiological evidence that elevated fibrinogen is a major risk factor for coronary heart disease...
- Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism riskPierre Yves Scarabin
INSERM Cardiovascular Epidemiology Unit U258, Villejuif, France
Lancet 362:428-32. 2003..Transdermal ERT has little effect on haemostasis, but data assessing its effect on thrombotic process are scarce. We aimed to examine the effect of the route of oestrogen administration on VTE risk...
- Endogenous oestradiol as a positive correlate of plasma fibrinogen among older postmenopausal women: a population-based study (the Three-City cohort study)Marianne Canonico
Hormones and Cardiovascular disease, Univ Paris Sud, Villejuif, France
Clin Endocrinol (Oxf) 77:905-10. 2012..However, whether endogenous sex steroid hormones influence the plasma fibrinogen concentrations among postmenopausal women remains unclear...
- Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administrationCeline Straczek
INSERM, Cardiovascular Epidemiology Unit, Villejuif, France
Circulation 112:3495-500. 2005..Transdermal estrogen may be safe with respect to VTE. We investigated the impact of the route of estrogen administration on the association between a prothrombotic mutation (factor V Leiden or prothrombin G20210A mutation) and VTE risk...
- A J-shaped association between plasma testosterone and risk of ischemic arterial event in elderly men: the French 3C cohort studyVéronique Soisson
INSERM U108, Center for Research in Epidemiology and Population Health, Hormones and Cardiovascular disease team, Villejuif, France
Maturitas 75:282-8. 2013..However, the relation between testosterone and cardiovascular disease is uncertain. We assessed the association of plasma sex hormones with the incidence of ischemic arterial disease (IAD) in elderly men...
- Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER studyMarianne Canonico
INSERM Unit 780, Cardiovascular Epidemiology Section, 16 Avenue Paul Vaillant Couturier, 94807 Villejuif Cedex, France
Circulation 115:840-5. 2007..Transdermal estrogen may be safer. However, currently available data have limited the ability to investigate the wide variety of types of progestogen...
- Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogenMarianne Canonico
Hormones and Cardiovascular disease, CESP Centre for researchin Epidemiology and Population Health, U1018, INSERM, Villejuif, France
Menopause 17:1122-7. 2010..However, the differential effects of progesterone and norpregnanes on hemostasis have not yet been investigated...
- Postmenopausal hormone therapy and cardiovascular disease: an overview of main findingsMarianne Canonico
INSERM Unit U780, Cardiovascular Section 16, avenue Paul Vaillant Couturier, 94807 Villejuif Cedex, France
Maturitas 54:372-9. 2006..Clinical research should be continued to assist patients and clinicians in making treatment decisions on the basis of an individual's benefits and risks...
- Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal womenValérie Olié
INSERM, CESP Centre for research in Epidemiology and Population Health, U1018, Hormones and Cardiovascular disease, Universite Paris Sud, UMRS 1018, Villejuif, France
Curr Opin Hematol 17:457-63. 2010..Transdermal estrogens may be safer but early results need to be confirmed. This review provides a summary of the most recent findings regarding the VTE risk among oral versus transdermal estrogens users...
- Association of postmenopausal hormone replacement therapy with carotid atherosclerosis and soluble thrombomodulin: the vascular aging (EVA) study. Etude du Vieillissement ArtérielLaure Petit
The National Institute of Health and Medical Research INSERM, Unit 258, Paris, France
Thromb Res 105:291-7. 2002..This suggests that the possible beneficial effects of HRT on atherosclerosis may not go through the endothelial cell damage assessed by plasma thrombomodulin...
- Hormone replacement therapy use is associated with a lower occurrence of carotid atherosclerotic plaques but not with intima-media thickness progression among postmenopausal women. The vascular aging (EVA) studyGregoire Le Gal
Unit 258, Institut National de la Sante et de la Recherche Medicale, Paris, France
Atherosclerosis 166:163-70. 2003..Information on the impact of hormone replacement therapy (HRT) on carotid atherosclerosis is limited. Moreover, transdermal estrogens have not been investigated...
- Sex-specific risk factors for recurrent venous thromboembolismValérie Olié
INSERM, CEPH Centre for research in Epidemiology and Population Health, U1018, Hormones and Cardiovascular disease team, F94807, Villejuif, France
Thromb Res 130:16-20. 2012..Men have higher risk of recurrent venous thromboembolism (VTE) than women but this sex difference remains unexplained. In addition, whether men and women share same risk factors for recurrent VTE is unclear...
- Hormone therapy and recurrence of venous thromboembolism among postmenopausal womenValérie Olié
Hormones and Cardiovascular disease team, CEPH Centre for research in Epidemiology and Population Health, U1018, INSERM, F94807, Villejuit, France
Menopause 18:488-93. 2011..However, the impact of transdermal estrogens on VTE recurrence risk has not been investigated. The aim of our study was to assess the impact of HT by route of estrogen administration on the risk of recurrent VTE...
- Increased thrombin generation among postmenopausal women using hormone therapy: importance of the route of estrogen administration and progestogensPierre Yves Scarabin
Inserm and University Paris XI, CESP Centre for research in Epidemiology and Population Health, UMR S 1018, Team 08 Hormones and Cardiovascular Disease, Villejuif, France
Menopause 18:873-9. 2011..Using calibrated automated thrombography, we tested the influence of the route of estrogen administration and progestogens on thrombin generation among postmenopausal women using hormone therapy...
- Association of influenza vaccination with reduced risk of venous thromboembolismTienan Zhu
Deparment of Vascular Medicine, University Paris Decartes and INSERM U765, Paris, France
Thromb Haemost 102:1259-64. 2009..71, 95% CI, 0.53-0.94) and for both provoked (OR 0.71, 95% CI, 0.53-0.97) and unprovoked VTE (OR 0.85, 95% CI, 0.59-1.23). This case-control study suggests that influenza vaccination is associated with a reduced risk of VTE...
- Low plasma testosterone and elevated carotid intima-media thickness: importance of low-grade inflammation in elderly menVéronique Soisson
Center for Research in Epidemiology and Population Health, Hormones and Cardiovascular disease, University Paris Sud, UMR S, Villejuif, France
Atherosclerosis 223:244-9. 2012..We investigated whether this association could be mediated or modified by traditional cardiovascular risk factors as well as inflammatory status...
- Progestogens and venous thromboembolism among postmenopausal women using hormone therapyMarianne Canonico
Centre for research in Epidemiology and Population Health, U1018, Hormones and Cardiovascular disease, Villejuif, France
Maturitas 70:354-60. 2011..In conclusion, progestogens may have differential effects on VTE risk according to the molecules and therefore represent an important potential determinant of the thrombotic risk among postmenopausal women using estrogens...
- Postmenopausal hormone therapy and venous thromboembolismValérie Olié
INSERM, CESP Centre for research in Epidemiology and Population Health, U1018, Hormones and Cardiovascular disease, F 94807 Villejuif, France
Thromb Res 127:S26-9. 2011..Because venous thromboembolism (VTE) is the main harmful effect of HT among young postmenopausal women, reducing VTE risk appears to be a relevant strategy to improve the benefit/risk profile of HT among postmenopausal women...
- High level of plasma estradiol as a new predictor of ischemic arterial disease in older postmenopausal women: the three-city cohort studyValérie Scarabin-Carré
Centre for research in Epidemiology and Population Health, Inserm Unit 1018, Hormones and Cardiovascular disease, Villejuif, France V S, M C, G P B, P Y S Université Paris Sud, UMR S 1018, Villejuif, France V S, M C, P D, P Y S
J Am Heart Assoc 1:e001388. 2012..Despite evidence that estrogens may be involved in atherothrombosis, the role of endogenous sex steroid hormones in ischemic arterial disease among postmenopausal women remains uncertain...
- Estrogen receptor alpha gene variants and major depressive episodesJoanne Ryan
INSERM, U 1061, Hôpital La Colombière, and University Montpellier 1, Montpellier, F 34000 France
J Affect Disord 136:1222-6. 2012..Despite evidence of estrogen's mood-enhancing effects, the association between estrogen receptor (ER) gene variants and lifetime major depression has been insufficiently studied...
- Increased thrombin generation is associated with acute ischemic stroke but not with coronary heart disease in the elderly: the Three-City cohort studyLaure Carcaillon
Institut National de la Sante et de la Recherche Medicale INSERM, Centre for research in Epidemiology and Population Health, U1018, Hormones and Cardiovascular disease, Villejuif, France
Arterioscler Thromb Vasc Biol 31:1445-51. 2011..Whether changes in this biomarker are relevant to arterial disease remains unknown. We investigated the association of thrombin generation with coronary heart disease (CHD) and acute ischemic stroke (AIS) in the elderly...
- Oestrogen receptor polymorphisms and late-life depressionJoanne Ryan
Inserm U1061, Hôpital La Colombière, 39 Avenue Charles Flahault, BP 34493, 34093 Montpellier Cedex 5, France
Br J Psychiatry 199:126-31. 2011..Evidence suggests a role for oestrogen in depression but the involvement of oestrogen receptor polymorphisms remains unknown...
- Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal womenMarianne Canonico
Institut National de la Santé et de la Recherche Médicale INSERM Unit 780 U780, Cardiovascular Epidemiology Section, 16 Avenue Paul Vaillant Couturier, Villejuif Cedex, F 94807 France
J Clin Endocrinol Metab 93:3082-7. 2008..This effect may be modulated by the expression of cytochromes P450 3A5 (CYP3A5) and 1A2 (CYP1A2) which are involved in the hepatic metabolism of estrogens...
- Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort studyMarianne Canonico
INSERM Unit 780, Cardiovascular Epidemiology Section, Cedex, France
Arterioscler Thromb Vasc Biol 30:340-5. 2010..Although recent data showed transdermal estrogens may be safe with respect to thrombotic risk, the impact of the route of estrogen administration and concomitant progestogens is not fully established...
- Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysisMarianne Canonico
INSERM Unit 780, Cardiovascular Epidemiology Section, Villejuif Cedex, France
BMJ 336:1227-31. 2008..To assess the risk of venous thromboembolism in women using hormone replacement therapy by study design, characteristics of the therapy and venous thromboembolism, and clinical background...
- Estrogens in vascular biology and disease: where do we stand today?Jean Francois Arnal
Department of Vascular Biology and Atherothrombosis, INSERM U858 I2MR, CHU Toulouse Rangueil, Toulouse, France
Curr Opin Lipidol 18:554-60. 2007..There is also evidence for a thrombogenic effect of oral estrogens. An understanding of the deleterious and beneficial effects of estrogens is thus required...
- Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17β-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised studyPascale Gaussem
Universite Paris Descartes, Paris, France
Thromb Haemost 105:560-7. 2011..This suggests that NOMAC/E2 could have a more favourable venous thromboembolism risk profile than LNG/EE; further epidemiological data are required to confirm this...
- Progestogen-only contraceptives and the risk of stroke: a meta-analysisZeina Chakhtoura
Department of Gynecology and Endocrinology, Hotel Dieu Hospital, AP HP, Paris Descartes University, Paris, France
Stroke 40:1059-62. 2009..The association between combined oral contraceptives (OC) use and increased risk of stroke has been reported. While progestogen-only contraceptives (POC) are commonly used worldwide, their impact on cardiovascular disease remains unclear...
- Estrogen receptor gene variants are associated with anxiety disorders in older womenJoanne Ryan
INSERM, U1061, Nervous System Pathologies Epidemiological and Clinical Research, Hôpital La Colombière, Montpellier, France
Psychoneuroendocrinology 36:1582-6. 2011..This study investigated whether ESR1 and ESR2 gene variants were associated with specific anxiety disorders in postmenopausal women and evaluated the potential modifying effect of hormone treatment (HT) on these associations...
- Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive proteinKarine Lacut
Departement de Medecine Interne, Hopital de la Cavale Blanche, Brest, France
Thromb Haemost 90:124-31. 2003..The clinical relevance of these effects remains to be determined...
- Estrogen plus progestin and risk of venous thrombosisPierre Yves Scarabin
JAMA 293:1322; author reply 1322-3. 2005
- Synergism between non-O blood group and oral estrogen in the risk of venous thromboembolism among postmenopausal women: The ESTHER studyMarianne Canonico
Thromb Haemost 99:246-8. 2008
- [Hormone therapy and risk of venous thromboembolism: new insights from the ESTHER study]Marianne Canonico
Med Sci (Paris) 24:228-31. 2008
- Is APC resistance a risk factor for venous thromboembolism in patients over 70 years?Emmanuel Oger
Groupe d Etude de la Thrombose de Bretagne Occidentale, Department of Internal Medicine and Chest Diseases, Hopital de la Cavale Blanche, F 29609 Brest Cedex, France
Thromb Haemost 88:587-91. 2002..8, 95% CI, 0.4 to 1.7). Age appeared as an effect-measure modifier with a significant interaction (p = 0.005). Our data suggest that APC resistance is not a risk factor for VTE in elderly...
- Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trialEmmanuel Oger
Departement de Medecine Interne, Hopital de la Cavale Blanche, Brest, France
Arterioscler Thromb Vasc Biol 23:1671-6. 2003..Oral estrogen replacement therapy (ERT) has been reported to induce APC resistance. Little is known about the effect of transdermal estrogen...
- Antithrombin Cambridge II (A384S): prevalence in patients of the Paris Thrombosis Study (PATHROS)Veronique Picard
Blood 110:2777-8. 2007
- Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart diseaseKhadija Lahlou-Laforet
Department of C L Psychiatry, Faculte de Medecine, Universite Paris Descartes, AP HP, Hopital Europeen Georges Pompidou, France
Am J Cardiol 97:1287-91. 2006....
- High plasma concentration of factor VIII coagulant is also a risk factor for venous thromboembolism in the elderlyEmmanuel Oger
Department of Internal Medicine and Chest Diseases, Hopital de la Cavale Blanche, F 29609 Brest Cedex, France
Haematologica 88:465-9. 2003..This study aimed to test the hypothesis that an association also exists in the elderly...